With considerable attention having been placed on RAS(off) inhibitors and growing interest in the dual RAF/MEK agents and on/off state agents from Nested Therapeutics, Frontier Medicines and Quanta Therapeutics, respectively, it’s all too easy to forget about the RAS(ON) inhibitors.

Meanwhile Revolution Medicines have trodden a different path and focused their efforts on targeting the active state of KRAS.

With clinical data likely coming up soon, we take a look at some of the science behind the curtain to see what to watch out for, including some red flags…

To learn more from our latest oncology review and get a heads up on key cancer research insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by